Combination therapy involving azacitidine for acute myeloid leukemia patients ineligible for intensive chemotherapy
Authors:
- 19 December 2024
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 148, 107638
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Upregulation of Tim‐3 is associated with poor prognosis in acute myeloid leukemiaCancer Medicine, 2022
- A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromesAnnals of Hematology, 2022
- Oral Azacitidine (CC-486) for the Treatment of Myeloid MalignanciesClinical Lymphoma Myeloma and Leukemia, 2022
- Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical ImplicationsStem Cell Reviews and Reports, 2022
- Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approachCancer, 2021
- Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?Blood Reviews, 2020
- Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2020
- Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid LeukemiaClinical Lymphoma Myeloma and Leukemia, 2019
- Ivosidenib: First Global ApprovalDrugs, 2018
- Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)Annals of Hematology, 2017